| Next revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:matinas_biopharma [2023/05/09 06:06]
liam created | pharmaceutical_companies:matinas_biopharma [2024/11/10 19:22] (current)
liam [External links] |
|---|
| |
| {{ :pharmaceutical_companies:mtnb_original.png?200|}} | {{ :pharmaceutical_companies:mtnb_original.png?200|}} |
| | |
| | **Matinas BioPharma** is an American biopharmaceutical company based in [[:united_states:new_jersey:Bedminster]], [[:united_states:New Jersey]]. |
| | |
| | ===== History ===== |
| | |
| | On January 10, 2019, Matinas announced it had entered an agreement with an undisclosed pharmaceutical company to "evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology."((Matinas BioPharma Holdings. (2019, January 10). //Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform.// GlobeNewswire News Room. https://web.archive.org/web/20230509042135/https://www.globenewswire.com/news-release/2019/01/10/1686096/32419/en/Matinas-BioPharma-Announces-a-Research-Evaluation-with-Top-Global-Pharma-Company-Based-on-Its-Proprietary-Drug-Delivery-Platform.html)) CEO [[:Jerome Jabbour]] said that the collaboration would "provide solutions for companies developing innovative nucleic acid polymers, small molecule drugs, [[:vaccines]], proteins and potentially even gene-editing technologies." |
| | |
| | ==== COVID-19 ==== |
| | |
| | In November 2020, Matinas received a $3.75 million award from the [[:Cystic Fibrosis Foundation]].((//LNC Platform.// Matinas BioPharma Holdings, Inc. Retrieved May 9, 2023, from http://archive.today/2023.05.09-041901/https://www.matinasbiopharma.com/lnc-technology/lnc-platform)) |
| | |
| | In December 2020, Matinas announced a collaboration with the [[:National Institute of Allergy and Infectious Diseases]] (NIAID) to evaluate oral formulations of [[Gilead Sciences]]’s antiviral drug [[:remdesivir]] in its potential treatment against [[:COVID-19]]. |
| | |
| | On April 11, 2022, Matinas and [[BioNTech]] announced a research collaboration "to evaluate a novel delivery technology for [[:mRNA vaccines|mRNA-based vaccines]]."((Zacks Equity Research. (2022, April 12). //Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines.// Nasdaq. https://web.archive.org/web/20220412202120/https://www.nasdaq.com/articles/matinas-mtnb-up-on-deal-with-biontech-for-mrna-vaccines)) |
| | |
| | In January 2023, Matinas and [[National Resilience]] "entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids."((Bhargava, A. (2023, January 23). //Matinas BioPharma Provides Business Update and 2023 Strategic Outlook.// Matinas BioPharma Holdings, Inc. http://archive.today/2023.01.31-021839/https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/439/matinas-biopharma-provides-business-update-and-2023)) In early 2023, the company sought funding from the [[:Biomedical Advanced Research and Development Authority]] (BARDA), and continued into its third project with [[Genentech]]. |
| | |
| | [[Gilead Sciences]] announced it had ended its partnership with Matinas in January 2023 in order to pursue their own [[:remdesivir]] "pro-drug".((Block, J. (2023, January 31). //Gilead abandons oral version of COVID drug remdesivir with Matinas Biopharma (NYSE:MTNB).// Seeking Alpha. https://web.archive.org/web/20230518231633/https://seekingalpha.com/news/3930004-gilead-abandons-oral-version-of-covid-drug-remdesivir-with-matinas-biopharma)) |
| | |
| | ===== Activities ===== |
| | |
| | Matinas is running clinical trials for MAT2203, a cryptococcal meningitis treatment, led by principal investigators [[:David Boulware]] and [[:David Meya]].((Matinas BioPharma Nanotechnologies, Inc., & University of Minnesota. (2022, September 15). //Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3.// ClinicalTrials.gov. https://web.archive.org/web/20230509041731/https://clinicaltrials.gov/ct2/show/NCT05541107)) |
| | |
| | ===== Organization ===== |
| | |
| | ==== Personnel ==== |
| | |
| | ^ Name ^ Position ^ Notes ^ |
| | | [[:Jerry Jabbour]] | Co-founder and CEO((//Jerry Jabbour, Matinas BioPharma Holdings inc: Profile and Biography.// Bloomberg. Retrieved May 18, 2023, from http://archive.today/2023.05.18-225130/https://www.bloomberg.com/profile/person/18631011)) | - | |
| | | [[:Abdel Fawzy]] | Co-founder and Executive VP((//Abdel A. Fawzy, Ph.d. | Matinas Biopharma | United States of America.// OMICS International. Retrieved May 18, 2023, from http://archive.today/2023.05.18-225547/https://biography.omicsonline.org/united-states-of-america/matinas-biopharma/abdel-a-fawzy-phd-1369145)) | - | |
| | |
| | ==== Investors ==== |
| | |
| | [[:SternAegis]] invested in Matinas in May 2013.((//Venture Round - MATINAS BIOPHARMA - 2013-05-17 - Crunchbase Funding Round Profile.// Crunchbase. Retrieved May 18, 2023, from https://www.crunchbase.com/funding_round/matinas-biopharma-series-unknown--c2ad135e)) |
| | |
| | ===== External links ===== |
| | |
| | * [[https://www.matinasbiopharma.com/|Website]] |
| | * [[https://wiki.whiteroseintelligence.com/en/Matinas-BioPharma|White Rose Wiki]] |
